Cite
HARVARD Citation
Nindra, U. et al. (2022). Elevated neutrophil‐to‐lymphocyte ratio (NLR) is associated with poorer progression‐free survival in unresectable stage III NSCLC treated with consolidation durvalumab. Thoracic cancer. 13 (21), pp. 3058-3062. [Online].